REFERENCES
1. Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16:589-604.
2. Llovet JM, Pinyol R, Kelley RK, et al. Molecular pathogenesis and systemic therapies for hepatocellular carcinoma. Nat Cancer. 2022;3:386-401.
3. Iavarone M, Nault JC, Cabibbo G, Torres F, Reig M. Indolent cancer and pattern of progression: two missing parameters in trial design for hepatology. Hepatology. 2024;79:1452-62.
4. Cabibbo G, Enea M, Attanasio M, Bruix J, Craxì A, Cammà C. A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. Hepatology. 2010;51:1274-83.
5. Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76:681-93.
6. Saltz LB. Curative-intent treatment for colorectal liver metastases: a medical oncologist’s perspective. Am Soc Clin Oncol Educ Book. 2012;32:205-8.
7. Trevisani F, Vitale A, Kudo M, et al. Merits and boundaries of the BCLC staging and treatment algorithm: learning from the past to improve the future with a novel proposal. J Hepatol. 2024;80:661-9.
8. Chen QF, Chen S, Chen M, Lyu N, Zhao M. Improving the conversion success rate of hepatocellular carcinoma: focus on the use of combination therapy with a high objective response rate. J Clin Transl Hepatol. 2024;12:298-304.
9. Sun HC, Zhou J, Wang Z, et al.; Alliance of Liver Cancer Conversion Therapy, Committee of Liver Cancer of the Chinese Anti-Cancer Association. Chinese expert consensus on conversion therapy for hepatocellular carcinoma (2021 edition). Hepatobiliary Surg Nutr. 2022;11:227-52.
10. Sun J, Guo R, Bi X, et al. Guidelines for diagnosis and treatment of hepatocellular carcinoma with portal vein tumor thrombus in China (2021 Edition). Liver Cancer. 2022;11:315-28.
11. Chan A, Zhang WY, Chok K, et al. ALPPS versus portal vein embolization for hepatitis-related hepatocellular carcinoma: a changing paradigm in modulation of future liver remnant before major hepatectomy. Ann Surg. 2021;273:957-65.
12. Ma Z, Xiao Z, Yin P, et al. Comparison of survival benefit and safety between surgery following conversion therapy versus surgery alone in patients with surgically resectable hepatocellular carcinoma at CNLC IIb/IIIa stage: a propensity score matching study. Int J Surg. 2024;110:2910-21.
13. Tran NH, Muñoz S, Thompson S, Hallemeier CL, Bruix J. Hepatocellular carcinoma downstaging for liver transplantation in the era of systemic combined therapy with anti-VEGF/TKI and immunotherapy. Hepatology. 2022;76:1203-18.
14. Vitale A, Cabibbo G, Iavarone M, et al.; HCC Special Interest Group of the Italian Association for the Study of the Liver. Personalised management of patients with hepatocellular carcinoma: a multiparametric therapeutic hierarchy concept. Lancet Oncol. 2023;24:e312-22.
15. European Association for the Study of the Liver. EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma. J Hepatol. 2025;82:315-74.
16. Ascari S, Chen R, Vivaldi C, et al. Advancements in immunotherapy for hepatocellular carcinoma. Expert Rev Anticancer Ther. 2025;25:151-65.
17. Finn RS, Qin S, Ikeda M, et al.; IMbrave150 Investigators. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382:1894-905.
18. Cheng AL, Qin S, Ikeda M, et al. Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2022;76:862-73.
19. Abou-Alfa GK, Lau G, Kudo M, et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid. 2022;1:EVIDoa2100070.
20. Rimassa L, Chan SL, Sangro B, et al. Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC. J Hepatol. 2025;83:899-908.
21. Galle PR, Decaens T, Kudo M, et al. Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): first results from CheckMate 9DW. J Clin Oncol. 2024;42:LBA4008.
22. Qin S, Chan SL, Gu S, et al.; CARES-310 Study Group. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study. Lancet. 2023;402:1133-46.
23. Kudo M, Aoki T, Ueshima K, et al. Achievement of complete response and drug-free status by atezolizumab plus bevacizumab combined with or without curative conversion in patients with transarterial chemoembolization-unsuitable, intermediate-stage hepatocellular carcinoma: a multicenter proof-of-concept study. Liver Cancer. 2023;12:321-38.
24. Tomonari T, Tani J, Sato Y, et al. Clinical features and outcomes of conversion therapy in patients with unresectable hepatocellular carcinoma. Cancers. 2023;15:5221.
25. Shimose S, Iwamoto H, Shirono T, et al. The impact of curative conversion therapy aimed at a cancer-free state in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab. Cancer Med. 2023;12:12325-35.
26. Ke Q, Xin F, Fang H, Zeng Y, Wang L, Liu J. The significance of transarterial chemo(embolization) combined with tyrosine kinase inhibitors and immune checkpoint inhibitors for unresectable hepatocellular carcinoma in the era of systemic therapy: a systematic review. Front Immunol. 2022;13:913464.
27. Sanduzzi-Zamparelli M, Cabibbo G. The “shell game” after objective response in patients with advanced HCC treated with immunotherapy. Hepatology. 2025;81:1635-7.
28. Xie DY, Zhu K, Ren ZG, Zhou J, Fan J, Gao Q. A review of 2022 Chinese clinical guidelines on the management of hepatocellular carcinoma: updates and insights. Hepatobiliary Surg Nutr. 2023;12:216-28.
29. Hasegawa K, Takemura N, Yamashita T, et al.; committee for Revision of the Clinical Practice Guidelines for Hepatocellular Carcinoma, Tokyo, Japan. Clinical Practice Guidelines for hepatocellular carcinoma: the Japan Society of Hepatology 2021 version (5th JSH-HCC Guidelines). Hepatol Res. 2023;53:383-90.
30. Kudo M. Current therapeutic strategies for hepatocellular carcinoma in Japan. Liver Cancer. 2023;12:497-509.
31. Lucatelli P, Burrel M, Guiu B, de Rubeis G, van Delden O, Helmberger T. CIRSE Standards of practice on hepatic transarterial chemoembolisation. Cardiovasc Intervent Radiol. 2021;44:1851-67.
32. Bartkowski R, Berger MR, Aguiar JL, et al. Experiments on the efficacy and toxicity of locoregional chemotherapy of liver tumors with 5-fluoro-2’-deoxyuridine (FUDR) and 5-fluorouracil (5-FU) in an animal model. J Cancer Res Clin Oncol. 1986;111:42-6.
33. Chen LT, Martinelli E, Cheng AL, et al. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO. Ann Oncol. 2020;31:334-51.
34. Miller FH, Lopes Vendrami C, Gabr A, et al. Evolution of radioembolization in treatment of hepatocellular carcinoma: a pictorial review. Radiographics. 2021;41:1802-18.
35. Garin E, Guiu B, Edeline J, Rolland Y, Palard X. Trans-arterial radioembolization dosimetry in 2022. Cardiovasc Intervent Radiol. 2022;45:1608-21.
36. Vitellius C, Desjonqueres E, Lequoy M, et al. MASLD-related HCC: multicenter study comparing patients with and without cirrhosis. JHEP Rep. 2024;6:101160.
37. Huang Z, Chen T, Li W, et al. Atezolizumab and bevacizumab plus transarterial chemoembolization and hepatic arterial infusion chemotherapy for patients with high tumor burden unresectable hepatocellular carcinoma: a multi-center cohort study. Int Immunopharmacol. 2024;139:112711.
38. Gan L, Lang M, Tian X, et al. A retrospective analysis of conversion therapy with lenvatinib, sintilimab, and arterially-directed therapy in patients with initially unresectable hepatocellular carcinoma. J Hepatocell Carcinoma. 2023;10:673-86.
39. Zhao W, Liu C, Wu Y, et al. Transarterial chemoembolization (TACE)-hepatic arterial infusion chemotherapy (HAIC) combined with PD-1 inhibitors plus lenvatinib as a preoperative conversion therapy for nonmetastatic advanced hepatocellular carcinoma: a single center experience. Transl Cancer Res. 2024;13:2315-31.
40. Lencioni R, Kudo M, Erinjeri J, et al. EMERALD-1: a phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization. J Clin Oncol. 2024;42:LBA432.
41. Kudo M, Ren Z, Guo Y, et al.; LEAP-012 investigators. Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study. Lancet. 2025;405:203-15.
42. Li X, Wang X, Bai T, et al. Conversion surgery for initially unresectable hepatocellular carcinoma using lenvatinib combined with TACE plus PD-1 inhibitor: a real-world observational study. Dig Liver Dis. 2024;56:1078-86.
43. Sun HC, Zhu XD. Downstaging conversion therapy in patients with initially unresectable advanced hepatocellular carcinoma: an overview. Front Oncol. 2021;11:772195.
44. Mazzaferro V, Citterio D, Bhoori S, et al. Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b/3 trial. Lancet Oncol. 2020;21:947-56.
45. Natarajan B, Tabrizian P, Hoteit M, et al. Downstaging hepatocellular carcinoma before liver transplantation: a multicenter analysis of the “all-comers” protocol in the Multicenter Evaluation of Reduction in Tumor Size before Liver Transplantation (MERITS-LT) consortium. Am J Transplant. 2023;23:1771-80.
46. Affonso BB, Galastri FL, da Motta Leal Filho JM, et al. Long-term outcomes of hepatocellular carcinoma that underwent chemoembolization for bridging or downstaging. World J Gastroenterol. 2019;25:5687-701.
47. Gabr A, Abouchaleh N, Ali R, et al. Outcomes of surgical resection after radioembolization for hepatocellular carcinoma. J Vasc Interv Radiol. 2018;29:1502-10.e1.
48. Salem R, Johnson GE, Kim E, et al. Yttrium-90 radioembolization for the treatment of solitary, unresectable HCC: the LEGACY study. Hepatology. 2021;74:2342-52.
49. Aliseda D, Martí-Cruchaga P, Zozaya G, et al. Liver resection and transplantation following yttrium-90 radioembolization for primary malignant liver tumors: a 15-year single-center experience. Cancers. 2023;15:733.
50. Tzedakis S, Sebai A, Jeddou H, et al. Resection postradioembolization in patients with single large hepatocellular carcinoma. Ann Surg. 2023;278:756-62.
51. Lewandowski RJ, Kulik LM, Riaz A, et al. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant. 2009;9:1920-8.
52. Mehta N, Frenette C, Tabrizian P, et al. Downstaging outcomes for hepatocellular carcinoma: results from the Multicenter Evaluation of Reduction in Tumor Size before Liver Transplantation (MERITS-LT) Consortium. Gastroenterology. 2021;161:1502-12.
53. Berardi G, Guglielmo N, Cucchetti A, et al. Transarterial radioembolization can downstage intermediate and advanced hepatocellular carcinoma to liver transplantation. Transplantation. 2025;109:e54-63.
54. Regnault H, Chalaye J, Galetto-Pregliasco A, et al. Selective internal radiation therapy for unresectable HCC: the SIRT downstaging study. Hepatol Commun. 2024;8:e0475.
55. Lim KC, Chow PK, Allen JC, Siddiqui FJ, Chan ES, Tan SB. Systematic review of outcomes of liver resection for early hepatocellular carcinoma within the Milan criteria. Br J Surg. 2012;99:1622-9.
56. Assalino M, Terraz S, Grat M, et al. Liver transplantation for hepatocellular carcinoma after successful treatment of macrovascular invasion - a multi-center retrospective cohort study. Transpl Int. 2020;33:567-75.
57. Meerun MA, Allimant C, Rivière B, et al. Large, multifocal or portal vein-invading hepatocellular carcinoma (HCC) downstaged by Y90 using personalized dosimetry: safety, pathological results and outcomes after surgery. Hepatobiliary Surg Nutr. 2023;12:351-65.
58. De la Garza-Ramos C, Toskich BB. Radioembolization for the treatment of hepatocellular carcinoma: the road to personalized dosimetry and ablative practice. Semin Intervent Radiol. 2021;38:466-71.
59. Vogel A, Meyer T, Sapisochin G, Salem R, Saborowski A. Hepatocellular carcinoma. Lancet. 2022;400:1345-62.
60. Huber TC, Bochnakova T, Koethe Y, Park B, Farsad K. Percutaneous therapies for hepatocellular carcinoma: evolution of liver directed therapies. J Hepatocell Carcinoma. 2021;8:1181-93.
61. Ahmed M, Brace CL, Lee FT Jr, Goldberg SN. Principles of and advances in percutaneous ablation. Radiology. 2011;258:351-69.
62. Di Costanzo GG, Tortora R, D’Adamo G, et al. Radiofrequency ablation versus laser ablation for the treatment of small hepatocellular carcinoma in cirrhosis: a randomized trial. J Gastroenterol Hepatol. 2015;30:559-65.
63. Tasu JP, Tougeron D, Rols MP. Irreversible electroporation and electrochemotherapy in oncology: state of the art. Diagn Interv Imaging. 2022;103:499-509.
64. Sutter O, Calvo J, N’Kontchou G, et al. Safety and efficacy of irreversible electroporation for the treatment of hepatocellular carcinoma not amenable to thermal ablation techniques: a retrospective single-center case series. Radiology. 2017;284:877-86.
65. Wu R, Shi Q, Liao D, et al. Efficacy and safety of antiangiogenic agents combined with HIFU in the treatment of advanced liver cancer. Front Oncol. 2025;15:1652434.
66. Han S, Sung PS, Park SY, et al. Local ablation for hepatocellular carcinoma: 2024 Expert Consensus-Based Practical Recommendations of the Korean Liver Cancer Association. Gut Liver. 2024;18:789-802.
67. Cillo U, Caregari S, Barabino M, et al. Hierarchically positioning laparoscopic microwave ablation in the therapeutic span of early hepatocellular carcinoma: a real-life comparative analysis. Ann Surg Oncol. 2025;32:1063-72.
68. Liu Q, Zhang R, Shen W. Advancements in locoregional therapy for advanced hepatocellular carcinoma: emerging perspectives on combined treatment strategies. Eur J Surg Oncol. 2025;51:109502.
69. Vitale A, Cabibbo G, Rimassa L, et al. The concept of "converse therapeutic hierarchy" for patients with hepatocellular carcinoma. Liver Cancer. 2025;14:743-57.
70. Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology. 2001;33:1394-403.
71. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693-9.
72. Yao FY, Mehta N, Flemming J, et al. Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria. Hepatology. 2015;61:1968-77.
73. Tabrizian P, Holzner ML, Mehta N, et al. Ten-year outcomes of liver transplant and downstaging for hepatocellular carcinoma. JAMA Surg. 2022;157:779-88.
74. Sun HC, Zhu XD. Downstaging conversion therapy in patients with initially unresectable advanced hepatocellular carcinoma: an overview. Front Oncol. 2021;11:772195.
75. Duan Y, Zhang H, Tan T, et al. The immune response of hepatocellular carcinoma after locoregional and systemic therapies: the available combination option for immunotherapy. Biosci Trends. 2024;17:427-44.
76. Memeo R, Conticchio M, Deshayes E, et al. Optimization of the future remnant liver: review of the current strategies in Europe. Hepatobiliary Surg Nutr. 2021;10:350-63.
77. Charles J, Nezami N, Loya M, et al. Portal vein embolization: rationale, techniques, and outcomes to maximize remnant liver hypertrophy with a focus on contemporary strategies. Life. 2023;13:279.
78. Chansangrat J, Keeratibharat N. Portal vein embolization: rationale, techniques, outcomes and novel strategies. Hepat Oncol. 2021;8:HEP42.
79. Shindoh J, Tzeng CWD, Vauthey JN. Portal vein embolization for hepatocellular carcinoma. Liver Cancer. 2012;1:159-67.
80. Aoki T, Kubota K. Preoperative portal vein embolization for hepatocellular carcinoma: consensus and controversy. World J Hepatol. 2016;8:439-45.
81. Glantzounis GK, Tokidis E, Basourakos SP, Ntzani EE, Lianos GD, Pentheroudakis G. The role of portal vein embolization in the surgical management of primary hepatobiliary cancers. a systematic review. Eur J Surg Oncol. 2017;43:32-41.
82. Beppu T, Yamamura K, Okabe H, Imai K, Hayashi H. Oncological benefits of portal vein embolization for patients with hepatocellular carcinoma. Ann Gastroenterol Surg. 2021;5:287-95.
83. Araki K, Shibuya K, Harimoto N, et al. A prospective study of sequential hepatic vein embolization after portal vein embolization in patients scheduled for right-sided major hepatectomy: results of feasibility and surgical strategy using functional liver assessment. J Hepatobiliary Pancreat Sci. 2023;30:91-101.
84. Park GC, Lee SG, Yoon YI, et al. Sequential transcatheter arterial chemoembolization and portal vein embolization before right hemihepatectomy in patients with hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2020;19:244-51.
85. Zhang CW, Dou CW, Zhang XL, et al. Simultaneous transcatheter arterial chemoembolization and portal vein embolization for patients with large hepatocellular carcinoma before major hepatectomy. World J Gastroenterol. 2020;26:4489-500.
86. Terasawa M, Allard MA, Golse N, et al. Sequential transcatheter arterial chemoembolization and portal vein embolization versus portal vein embolization alone before major hepatectomy for patients with large hepatocellular carcinoma: an intent-to-treat analysis. Surgery. 2020;167:425-31.
87. Niekamp AS, Huang SY, Mahvash A, et al. Hepatic vein embolization after portal vein embolization to induce additional liver hypertrophy in patients with metastatic colorectal carcinoma. Eur Radiol. 2020;30:3862-8.
88. Smits J, Chau S, James S, et al.; EuroLVD and DRAGON Trials Collaborative. Combined portal and hepatic vein embolisation in perihilar cholangiocarcinoma. HPB. 2024;26:1458-66.
89. Esposito F, Lim C, Lahat E, et al. Combined hepatic and portal vein embolization as preparation for major hepatectomy: a systematic review. HPB. 2019;21:1099-106.
90. Schadde E. Combined portal vein and hepatic vein embolization-finally the platinum procedure of regenerative liver surgery? Hepatobiliary Surg Nutr. 2020;9:92-4.
91. Baili E, Tsilimigras DI, Moris D, Sahara K, Pawlik TM. Technical modifications and outcomes after associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) for primary liver malignancies: a systematic review. Surg Oncol. 2020;33:70-80.
92. Lau WY, Lai EC, Lau SH. Associating liver partition and portal vein ligation for staged hepatectomy: the current role and development. Hepatobiliary Pancreat Dis Int. 2017;16:17-26.
93. Xiang F, Hu ZM. Chance and challenge of associating liver partition and portal vein ligation for staged hepatectomy. Hepatobiliary Pancreat Dis Int. 2019;18:214-22.
94. Nikokiraki C, Psaraki A, Roubelakis MG. The potential clinical use of stem/progenitor cells and organoids in liver diseases. Cells. 2022;11:1410.
95. So J, Kim A, Lee SH, Shin D. Liver progenitor cell-driven liver regeneration. Exp Mol Med. 2020;52:1230-8.
96. Cardinale V, Lanthier N, Baptista PM, et al. Cell transplantation-based regenerative medicine in liver diseases. Stem Cell Reports. 2023;18:1555-72.
97. Zahmatkesh E, Khoshdel Rad N, Hossein-Khannazer N, et al. Cell and cell-derivative-based therapy for liver diseases: current approaches and future promises. Expert Rev Gastroenterol Hepatol. 2023;17:237-49.
98. Nevola R, Ruocco R, Criscuolo L, et al. Predictors of early and late hepatocellular carcinoma recurrence. World J Gastroenterol. 2023;29:1243-60.
99. Xu XF, Xing H, Han J, et al. Risk factors, patterns, and outcomes of late recurrence after liver resection for hepatocellular carcinoma: a multicenter study from China. JAMA Surg. 2019;154:209-17.
100. Fuster-Anglada C, Mauro E, Ferrer-Fàbrega J, et al. Histological predictors of aggressive recurrence of hepatocellular carcinoma after liver resection. J Hepatol. 2024;81:995-1004.
101. Poon R, Fan ST, Wong J. Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann Surg. 2000;232:10-24.
102. Yamanaka N, Tanaka T, Tanaka W, et al. Correlation of hepatitis virus serologic status with clinicopathologic features in patients undergoing hepatectomy for hepatocellular carcinoma. Cancer. 1997;79:1509-15.
103. Fung AKY, Cheng NMY, Chong CCN, et al. Single-center experience on actual mid-term (≥5 years) and long-term (≥10 years) survival outcome in patients with hepatocellular carcinoma after curative hepatectomy: a bimodal distribution. Medicine. 2020;99:e23358.
104. Shirabe K, Sugimachi K, Harada N, et al. Favorable prognosis in patients with sustained virological response to antiviral therapy, including interferon, for chronic hepatitis C before hepatic resection for hepatocellular carcinoma. Anticancer Res. 2015;35:6963-9.
105. Zhou Y, Si X, Wu L, Su X, Li B, Zhang Z. Influence of viral hepatitis status on prognosis in patients undergoing hepatic resection for hepatocellular carcinoma: a meta-analysis of observational studies. World J Surg Oncol. 2011;9:108.
106. Arnaoutakis DJ, Mavros MN, Shen F, et al. Recurrence patterns and prognostic factors in patients with hepatocellular carcinoma in noncirrhotic liver: a multi-institutional analysis. Ann Surg Oncol. 2014;21:147-54.
107. Kim JM, Kwon CH, Joh JW, et al. Differences between hepatocellular carcinoma and hepatitis B virus infection in patients with and without cirrhosis. Ann Surg Oncol. 2014;21:458-65.
108. Lee HW, Choi GH, Kim DY, et al. Less fibrotic burden differently affects the long-term outcomes of hepatocellular carcinoma after curative resection. Oncology. 2017;93:224-32.
109. D’Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol. 2006;44:217-31.
110. Piano S, Reiberger T, Bosch J. Mechanisms and implications of recompensation in cirrhosis. JHEP Rep. 2024;6:101233.
111. Lampertico P, Invernizzi F, Viganò M, et al. The long-term benefits of nucleos(t)ide analogs in compensated HBV cirrhotic patients with no or small esophageal varices: a 12-year prospective cohort study. J Hepatol. 2015;63:1118-25.
112. Nguyen MH, Keeffe EB. Chronic hepatitis B: early viral suppression and long-term outcomes of therapy with oral nucleos(t)ides. J Viral Hepat. 2009;16:149-55.
113. Jang JW, Choi JY, Kim YS, et al. Long-term effect of antiviral therapy on disease course after decompensation in patients with hepatitis B virus-related cirrhosis. Hepatology. 2015;61:1809-20.
114. Cholongitas E, Papatheodoridis GV, Goulis J, et al. The impact of newer nucleos(t)ide analogues on patients with hepatitis B decompensated cirrhosis. Ann Gastroenterol. 2015;28:109-17.
115. Zhang Y, Liu X, Li S, et al. Risk of HCC decreases in HBV-related patients with cirrhosis acquired recompensation: a retrospective study based on Baveno VII criteria. Hepatol Commun. 2024;8:e0355.
116. Yu SJ, Kim YJ. Hepatitis B viral load affects prognosis of hepatocellular carcinoma. World J Gastroenterol. 2014;20:12039-44.
117. Shim JJ. Long-term suppression of viral replication in chronic hepatitis B: outcomes and future directions. Gut Liver. 2015;9:265-6.
118. Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7:6.
119. Singal AG, Kanwal F, Llovet JM. Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy. Nat Rev Clin Oncol. 2023;20:864-84.
120. Kim DY. Changing etiology and epidemiology of hepatocellular carcinoma: Asia and worldwide. J Liver Cancer. 2024;24:62-70.
121. Vibert E, Schwartz M, Olthoff KM. Advances in resection and transplantation for hepatocellular carcinoma. J Hepatol. 2020;72:262-76.
122. Roayaie S, Haim MB, Emre S, et al. Comparison of surgical outcomes for hepatocellular carcinoma in patients with hepatitis B versus hepatitis C: a western experience. Ann Surg Oncol. 2000;7:764-70.
123. Franssen B, Alshebeeb K, Tabrizian P, et al. Differences in surgical outcomes between hepatitis B- and hepatitis C-related hepatocellular carcinoma: a retrospective analysis of a single North American center. Ann Surg. 2014;260:650-8.
124. Singal AG, Rich NE, Mehta N, et al. Direct-acting antiviral therapy for hepatitis C virus infection is associated with increased survival in patients with a history of hepatocellular carcinoma. Gastroenterology. 2019;157:1253-63.e2.
125. Singal AG, Rich NE, Mehta N, et al. Direct-acting antiviral therapy not associated with recurrence of hepatocellular carcinoma in a multicenter North American cohort study. Gastroenterology. 2019;156:1683-92.e1.
126. Cabibbo G, Celsa C, Calvaruso V, et al.; Rete Sicilia Selezione Terapia - HCV (RESIST-HCV) and Italian Liver Cancer (ITA.LI.CA.) Group. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients. J Hepatol. 2019;71:265-73.
127. Kamp WM, Sellers CM, Stein S, Lim JK, Kim HS. Direct-acting antivirals improve overall survival in interventional oncology patients with hepatitis C and hepatocellular carcinoma. J Vasc Interv Radiol. 2020;31:953-60.
128. Gorgen A, Galvin Z, Huang AC, et al. The impact of direct-acting antivirals on overall mortality and tumoral recurrence in patients with hepatocellular carcinoma listed for liver transplantation: an international multicenter study. Transplantation. 2020;104:2087-96.
129. Reig M, Mariño Z, Perelló C, et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol. 2016;65:719-26.
130. Conti F, Buonfiglioli F, Scuteri A, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol. 2016;65:727-33.
131. Tsai PC, Huang CF, Yu ML. Unexpected early tumor recurrence in patients with hepatitis C virus-related hepatocellular carcinoma undergoing interferon-free therapy: issue of the interval between HCC treatment and antiviral therapy. J Hepatol. 2017;66:464.
132. Lui FH, Moosvi Z, Patel A, et al. Decreased risk of hepatocellular carcinoma recurrence with direct-acting antivirals compared with no treatment for hepatitis C: a meta-analysis. Ann Gastroenterol. 2020;33:293-8.
133. Reiberger T, Lens S, Cabibbo G, et al. EASL position paper on clinical follow-up after HCV cure. J Hepatol. 2024;81:326-44.
134. Mezzacappa C, Kim NJ, Vutien P, Kaplan DE, Ioannou GN, Taddei TH. Screening for hepatocellular carcinoma and survival in patients with cirrhosis after hepatitis C virus cure. JAMA Netw Open. 2024;7:e2420963.
135. Semmler G, Meyer EL, Kozbial K, et al. HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease. J Hepatol. 2022;76:812-21.
136. Hofer BS, Simbrunner B, Hartl L, et al. Alcohol abstinence improves prognosis across all stages of portal hypertension in alcohol-related cirrhosis. Clin Gastroenterol Hepatol. 2023;21:2308-17.e7.
137. Rodríguez M, González-Diéguez ML, Varela M, et al. Impact of alcohol abstinence on the risk of hepatocellular carcinoma in patients with alcohol-related liver cirrhosis. Am J Gastroenterol. 2021;116:2390-8.
138. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). Obes Facts. 2024;17:374-444.
139. Lange NF, Radu P, Dufour JF. Prevention of NAFLD-associated HCC: role of lifestyle and chemoprevention. J Hepatol. 2021;75:1217-27.
140. Njei B, McCarty TR, Sharma P, et al. Bariatric surgery and hepatocellular carcinoma: a propensity score-matched analysis. Obes Surg. 2018;28:3880-9.
141. Zou B, Odden MC, Nguyen MH. Statin use and reduced hepatocellular carcinoma risk in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2023;21:435-44.e6.
142. Pinyopornpanish K, Al-Yaman W, Butler RS, Carey W, McCullough A, Romero-Marrero C. Chemopreventive effect of statin on hepatocellular carcinoma in patients with nonalcoholic steatohepatitis cirrhosis. Am J Gastroenterol. 2021;116:2258-69.
143. Stefanini B, Manfredi GF, D’Alessio A, et al. Delivering adjuvant and neoadjuvant treatments in the early stages of hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol. 2024;18:647-60.
144. Cabibbo G, Celsa C, Rimassa L, et al. Navigating the landscape of liver cancer management: Study designs in clinical trials and clinical practice. J Hepatol. 2024;80:957-66.
145. Mazzaferro V, Romito R, Schiavo M, et al.; HCC Italian Task Force. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology. 2006;44:1543-54.
146. Chen LT, Chen MF, Li LA, et al.; Disease Committee of Adjuvant Therapy for Postoperative Hepatocellular Carcinoma, Taiwan; Cooperative Oncology Group, National Health Research Institutes, Zhunan, Taiwan. Long-term results of a randomized, observation-controlled, phase III trial of adjuvant interferon Alfa-2b in hepatocellular carcinoma after curative resection. Ann Surg. 2012;255:8-17.
147. Bruix J, Takayama T, Mazzaferro V, et al.; STORM investigators. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2015;16:1344-54.
148. Lee JH, Lee JH, Lim YS, et al. Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma. Gastroenterology. 2015;148:1383-91.e6.
149. Qin S, Chen M, Cheng AL, et al.; IMbrave050 investigators. Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2023;402:1835-47.
150. Yopp A, Kudo M, Chen M, et al. LBA39 Updated efficacy and safety data from IMbrave050: Phase III study of adjuvant atezolizumab (atezo) + bevacizumab (bev) vs active surveillance in patients (pts) with resected or ablated high-risk hepatocellular carcinoma (HCC). Ann Oncol. 2024;35:S1230.
151. Wang K, Xiang YJ, Yu HM, et al. Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial. Nat Med. 2024;30:708-15.
152. Zhang S, Yuan L, Danilova L, et al. Spatial transcriptomics analysis of neoadjuvant cabozantinib and nivolumab in advanced hepatocellular carcinoma identifies independent mechanisms of resistance and recurrence. Genome Med. 2023;15:72.
153. Marron TU, Fiel MI, Hamon P, et al. Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial. Lancet Gastroenterol Hepatol. 2022;7:219-29.
154. LaPelusa M, Chamseddine S, Tran Cao HS, et al. Tissue and imaging biomarkers of response to neoadjuvant nivolumab or nivolumab plus ipilimumab in patients with resectable hepatocellular carcinoma. Oncology. 2025;103:490-7.
